Article Figures & Data
Figures
- Figure 1.
Schematic representation of the approach used for candidate miRNA biomarker selection in this study. HC, healthy control.
- Figure 2.
Serum levels of candidate miRNA biomarkers in the screening phase. Levels of serum miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-24, miR-29a, miR-92a, and miR-125b were compared between healthy controls (HC) and early colorectal neoplasm patients. The Mann–Whitney U test was performed for comparisons between groups.
- Figure 3.
Serum miR-21, miR-29a, and miR-125b in the validation phase. A, levels of miRNAs were compared between healthy controls (HC) and early colorectal neoplasia patients. Statistical analyses were performed using the Mann–Whitney U test. B, levels of miRNAs were compared among HCs, patients with non-advanced neoplasia (AN) colorectal neoplasms (non-AN), and patients with ANs (AN). All-pairs multiple comparison was conducted by the Steel–Dwass test. C, correlation between levels of serum miRNAs and the size of the index lesion. Spearman rank correlation coefficient (ρ) is shown.
- Figure 4.
ROC curves for miR-21, miR-29a, miR-125b and the combination of the 3 miRNAs in discriminating patients with early colorectal neoplasms from healthy controls (HCs; A) and in discriminating patients with advanced neoplasias (AN) from individuals without ANs (B). AUC values are shown.
- Figure 5.
A, serum miR-21, miR-29a, and miR-125b in patients with small colorectal neoplasms. Levels of miRNAs were compared among healthy controls (HC), patients with small colorectal neoplasms (total diameter of colorectal neoplasms in an individual ≤ 5 mm, sCRN), and those with larger colorectal neoplasms (total diameter of colorectal neoplasms > 5 mm, non-sCRN). All-pairs multiple comparison was conducted by the Steel–Dwass test. B, serum miRNA levels according to various histologic subtypes of colorectal neoplasms. Statistical analysis was conducted by the Steel–Dwass test, and significant differences of miRNA levels compared with HCs are noted. a, P < 0.05; b, P < 0.01; c, P < 0.0001.
Tables
- Table 1.
Clinicopathologic characteristics of study subjects
Screening set Validation set HC CRN HC CRN (n = 25) (n = 24) (n = 52) (n = 136) Age, y Median (range) 34 (22–49) 67 (37–84) 58 (23–77) 68 (37–86) Gender Male (%) 19 (76.0) 13 (54.2) 23 (44.2) 93 (68.4) Female (%) 6 (24.0) 11 (45.8) 29 (55.8) 43 (31.6) Locationa Right (%) — 13 (54.2) — 32 (23.7) Left (%) — 7 (29.2) — 55 (40.7) Both (%) — 4 (16.7) — 48 (35.6) Morphology Protruded (%) — 3 (12.5) — 45 (33.1) Superficial (%) — 13 (54.2) — 59 (43.4) Both (%) — 8 (33.3) — 32 (23.5) Size of the index lesion, mm Median (range) — 8 (4–32) — 10 (3–55) Number of neoplastic lesions Median (range) — 2 (1–9) — 1.5 (1–16) Histology of the index lesion LGIN — 12 (50.0) — 94 (69.1) Tubular adenoma — 12 (50.0) — 70 (51.5) Tubulovillous adenoma — 0 (0.0) — 15 (11.0) Sessile serrated polyp/adenoma — 0 (0.0) — 5 (3.7) Traditional serrated adenoma — 0 (0.0) — 2 (1.5) Mixed serrated polyp — 0 (0.0) — 2 (1.5) HGIN — 8 (33.3) — 34 (25.0) Cancer — 4 (16.7) — 8 (5.9) Abbreviations: HC, healthy control, CRN, colorectal neoplasia.
↵aLocation of one case in the validation phase was unknown.
Supplementary Data
- Figure Legends for Supplementary Figures - Figure Legends for Supplementary Figures
- Supplementary Figure 1 - Supplementary figure 1: Expression levels of serum miR-21, miR-29a and miR-125b in healthy controls (HC) vs. patients with colorectal neoplasms (CRN), after exclusion of 8 patients with colorectal cancer.
- Supplementary Figure 2 - Supplementary figure 2: Kaplan Meier survival curves based upon expression levels of miR-21, miR-29a, miR-125b and their combination, when comparing patients with colorectal neoplasms (CRN) with healthy controls (HC), and when comparing patients with advanced neoplasms (AN) with patients without advanced neoplasms (non-AN), after exclusion of all patients with colorectal cancer.
Volume 21, Issue 18
